Inhibitors of the Influenza A Virus M2 Proton Channel Discovered Using a High-Throughput Yeast Growth Restoration Assay

Balgi, Aruna D.; Wang, Jun; Cheng, Daphne Y. H.; Ma, Chunlong; Pfeifer, Tom A.; Shimizu, Yoko; Anderson, Hilary J.; Pinto, Lawrence H.; Lamb, Robert A.; DeGrado, William F.; Roberge, Michel
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
The M2 proton channel of the influenza A virus is the target of the anti-influenza drugs amantadine and rimantadine. The effectiveness of these drugs has been dramatically limited by the rapid spread of drug resistant mutations, mainly at sites S31N, V27A and L26F in the pore of the channel. Despite progress in designing inhibitors of V27A and L26F M2, there are currently no drugs targeting these mutated channels in clinical trials. Progress in developing new drugs has been hampered by the lack of a robust assay with sufficient throughput for discovery of new active chemotypes among chemical libraries and sufficient sensitivity to provide the SAR data essential for their improvement and development as drugs. In this study we adapted a yeast growth restoration assay, in which expression of the M2 channel inhibits yeast growth and exposure to an M2 channel inhibitor restores growth, into a robust and sensitive high-throughput screen for M2 channel inhibitors. A screen of over 250,000 pure chemicals and semi-purified fractions from natural extracts identified 21 active compounds comprising amantadine, rimantadine, 13 related adamantanes and 6 non-adamantanes. Of the non-adamantanes, hexamethylene amiloride and a triazine derivative represented new M2 inhibitory chemotypes that also showed antiviral activity in a plaque reduction assay. Of particular interest is the fact that the triazine derivative was not sufficiently potent for detection as an inhibitor in the traditional two electrode voltage clamp assay for M2 channel activity, but its discovery in the yeast assay led to testing of analogues of which one was as potent as amantadine.


Related Articles

  • Oseltamivir (Tamiflu) Resistance in Seasonal Influenza A (H1N1) Viruses. Scully, Mary-Louise // Travel Medicine Advisor;Feb2009, Vol. 19 Issue 2, p5 

    INFLUENZA ACTIVITY HAS BEEN RELATIVELY LOW THUS FAR IN THE 2008-2009 season in the United States. However, of the influenza viruses isolated and tested to date there is significant resistance among the influenza A (H1N1) viruses to the antiviral oseltamivir. As of mid-December 2008, 50 influenza...

  • Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction. Söderholm, Sandra; Yu Fu; Gaelings, Lana; Belanov, Sergey; Yetukuri, Laxman; Berlinkov, Mikhail; Cheltsov, Anton V.; Anders, Simon; Aittokallio, Tero; Nyman, Tuula A.; Matikainen, Sampsa; Kainov, Denis E. // Viruses (1999-4915);Oct2016, Vol. 8 Issue 10, p1 

    Human influenza A viruses (IAVs) cause global pandemics and epidemics. These viruses evolve rapidly, making current treatment options ineffective. To identify novel modulators of IAV-host interactions, we re-analyzed our recent transcriptomics, metabolomics, proteomics, phosphoproteomics, and...

  • Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs. Dapat, Clyde; Suzuki, Yasushi; Saito, Reiko; Kyaw, Yadanar; Myint, Yi Yi; Lin, Nay; Oo, Htun Naing; Oo, Khin Yi; Win, Ne; Naito, Makoto; Hasegawa, Go; Dapat, Isolde C.; Zaraket, Hassan; Baranovich, Tatiana; Nishikawa, Makoto; Saito, Takehiko; Suzuki, Hiroshi // Emerging Infectious Diseases;Mar2010, Vol. 16 Issue 3, p493 

    In 2007 and 2008 in Myanmar, we detected influenza viruses A (H3N2) that exhibited reduced sensitivity to both zanamivir and amantadine. These rare and naturally occurring viruses harbored a novel Q136K mutation in neuraminidase and S31N mutation in M2.

  • R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses. Sleeman, Katrina; Guo, Zhu; Barnes, John; Shaw, Michael; Stevens, James; Gubareva, Larisa V. // Emerging Infectious Diseases;Sep2013, Vol. 19 Issue 9, p1521 

    Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral...

  • How to beat the flu.  // Consumer Reports;Nov2000, Vol. 65 Issue 11, p64 

    Offers advice on how to prevent and treat influenza. Statement by the United States Centers for Disease Control and Prevention (CDC) that everyone age 50 and over should get a flu shot; Use of antiviral drugs, such as amantadine and zanamivir, to combat the flu; Common symptoms of influenza,...

  • ANTIVIRALS FOR INFLUENZA. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2009, p136 

    The article presents information on antivirals for influenza with generic names such as amantadine and rimantadine and brand names such as Symadine, Symmetrel and Flumadine, including dosage, usage, adverse reactions, side effects, precautions, and possible interaction with other drugs.

  • Influenza '99: New antiviral approved, flu shot season begins.  // Geriatrics;Sep99, Vol. 54 Issue 9, p12 

    Reports on the approval of antiviral agent, zanamivir, by the United States (US) Food and Drug Administration for the treatment of influenza. Comparison of zanamivir with amantadine and rimantadine; Investigations done on the effectiveness of the drug in flu prevention; Mortality of the flu...

  • Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Cady, Sarah D.; Schmidt-Rohr, Klaus; Jun Wang; Soto, Cinque S.; DeGrado, William F.; Mei Hong // Nature;2/4/2010, Vol. 463 Issue 7281, p689 

    The M2 protein of influenza A virus is a membrane-spanning tetrameric proton channel targeted by the antiviral drugs amantadine and rimantadine. Resistance to these drugs has compromised their effectiveness against many influenza strains, including pandemic H1N1. A recent crystal structure of...

  • Determinants of Antiviral Effectiveness in Influenza Virus A Subtype H5N1. Chan, Paul K. S.; Lee, Nelson; Zaman, Mukhtiar; Adisasmito, Wiku; Coker, Richard; Hanshaoworakul, Wanna; Gasimov, Viktor; Oner, Ahmet Faik; Dogan, Nazim; Tsang, Owen; Phommasack, Bounlay; Touch, Sok; Bamgboye, Ebun; Swenson, Anna; Toovey, Stephen; Dreyer, Nancy A. // Journal of Infectious Diseases;Nov2012, Vol. 206 Issue 9, p1359 

    Background. Oseltamivir is widely used as treatment for influenza virus A subtype H5N1 (hereafter, “H5N1”) infection but, like any intervention, is not always effective.Methods. We used Avian Influenza Registry data from 10 countries to examine the risk of death in 215 patients with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics